With Remicade Biosimilar On The Rise, J&J Adds Astellas’ JAK2 To Pipeline
This article was originally published in The Pink Sheet Daily
Executive Summary
The unknowns of JAK inhibitors still offer substantial promise, and Pfizer will likely be the first test subject in the RA space.